Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC 707545) in Patients With Solid Tumors

Trial Profile

Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC 707545) in Patients With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2013

At a glance

  • Drugs Alvespimycin (Primary)
  • Indications Breast cancer; Colon cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Dec 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Feb 2008 Kosan has reported that this trial is to be discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top